NanoBio Closes $10 Million Series A Round, Changes Name To BlueWillow Biologics
ANN ARBOR — NanoBio Corp., a clinical-stage biopharmaceutical company, announced that it has changed its corporate name to BlueWillow Biologics in conjunction with the closing of a $10 million Series A financing. The company’s new name reflects its evolution to a vaccines-focused company, and commitment to advancing its novel intranasal technology to develop new vaccines